Financings In Brief: Vical
Executive Summary
Vical: Gene therapy R&D firm files registration for secondary offering of 2.5 mil. share of common stock with SEC, San Diego-based Vical announces Aug. 15. All shares are beings sold by the company, with Goldman, Sachs and Cowen & Co. managing the offer. Proceeds will be used for R&D expenses, including preclinical testing and clinical trials...